|
1
|
Kuznia AL and Roett MA: Genital cancers in
women: Ovarian cancer. FP Essent. 438:24–30. 2015.PubMed/NCBI
|
|
2
|
Nicoletto MO, Artioli G, Donach M, Sileni
VC, Monfardini S, Talamini R, Veronesi A, Ferrazzi E, Tumolo S,
Visonà E, et al: Elderly ovarian cancer: Treatment with
mitoxantrone-carboplatin. Gynecol Oncol. 80:221–226. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rustin GJ, van der Burg ME, Griffin CL,
Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C,
Qian W, et al: Early versus delayed treatment of relapsed ovarian
cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet.
376:1155–1163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harries M and Gore M: Part II:
Chemotherapy for epithelial ovarian cancer-treatment of recurrent
disease. Lancet Oncol. 3:537–545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sundar S, Neal RD and Kehoe S: Diagnosis
of ovarian cancer. BMJ. 351:h44432015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qian Q, Yan Y, Yang J, Cao D, Zhu Z, Wu M,
Chen J, Lang J and Shen K: Management and prognosis of patients
with ovarian sex cord tumor with annular tubules: A retrospective
study. BMC Cancer. 15:2702015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirato H, Ogawa S, Nakajima K, Inagawa M,
Kojima M, Tachibana M, Shinkai Y and Takeuchi T: A jumonji (Jarid2)
protein complex represses cyclin D1 expression by methylation of
histone H3-K9. J Biol Chem. 284:733–739. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sanulli S, Justin N, Teissandier A,
Ancelin K, Portoso M, Caron M, Michaud A, Lombard B, da Rocha ST,
Offer J, et al: Jarid2 Methylation via the PRC2 complex regulates
H3K27me3 deposition during cell differentiation. Mol Cell.
57:769–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Landeira D, Sauer S, Poot R, Dvorkina M,
Mazzarella L, Jørgensen HF, Pereira CF, Leleu M, Piccolo FM,
Spivakov M, et al: Jarid2 is a PRC2 component in embryonic stem
cells required for multi-lineage differentiation and recruitment of
PRC1 and RNA Polymerase II to developmental regulators. Nat Cell
Biol. 12:618–624. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng JC, Valouev A, Swigut T, Zhang J,
Zhao Y, Sidow A and Wysocka J: Jarid2/Jumonji coordinates control
of PRC2 enzymatic activity and target gene occupancy in pluripotent
cells. Cell. 139:1290–1302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Walters ZS, Villarejo-Balcells B, Olmos D,
Buist TW, Missiaglia E, Allen R, Al-lazikani B, Garrett MD, Blagg J
and Shipley J: JARID2 is a direct target of the PAX3-FOXO1 fusion
protein and inhibits myogenic differentiation of rhabdomyosarcoma
cells. Oncogene. 33:1148–1157. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tange S, Oktyabri D, Terashima M, Ishimura
A and Suzuki T: JARID2 is involved in transforming growth
factor-beta-induced epithelial-mesenchymal transition of lung and
colon cancer cell lines. PLoS One. 9:e1156842014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu Z, Tang LS, Xu L, Qin X, Mao S, Song
Y, Liu L, Li F, Liu P, Yi L, et al: Genome-wide association study
identifies new susceptibility loci for adolescent idiopathic
scoliosis in Chinese girls. Nat Commun. 6:83552015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lei X, Xu JF, Chang RM, Fang F, Zuo CH and
Yang LY: JARID2 promotes invasion and metastasis of hepatocellular
carcinoma by facilitating epithelial-mesenchymal transition through
PTEN/AKT signaling. Oncotarget. 7:40266–40284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-tie quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L, Wang L, Zhang W, Tang B, Zhang J,
Song H, Yao D, Tang Y, Chen X, Yang Z, et al: Correlation of serum
VEGF levels with clinical stage, therapy efficacy, tumor metastasis
and patient survival in ovarian cancer. Anticancer Res.
24:1973–1979. 2004.PubMed/NCBI
|
|
17
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metast Rev.
28:15–33. 2009. View Article : Google Scholar
|
|
19
|
Meng Q, Xia C, Fang J, Rojanasakul Y and
Jiang BH: Role of PI3K and AKT specific isoforms in ovarian cancer
cell migration, invasion and proliferation through the p70S6K1
pathway. Cell Signal. 18:2262–2271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang J, Zhang L, Greshock J, Colligon TA,
Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al:
Frequent genetic abnormalities of the PI3K/AKT pathway in primary
ovarian cancer predict patient outcome. Genes Chromosomes Cancer.
50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grille SJ, Bellacosa A, Upson J,
Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and
Larue L: The protein kinase Akt induces epithelial mesenchymal
transition and promotes enhanced motility and invasiveness of
squamous cell carcinoma lines. Cancer Res. 63:2172–2178.
2003.PubMed/NCBI
|
|
25
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
|
